Pharmacy Benefits Management

September 28, 2021

September 28, 2021 – The U.S. FDA has approved Eli Lilly's Erbitux® (cetuximab) for use with Pfizer's Braftovi® (encorafenib) to treat metastatic colorectal cancer (CRC)
September 21, 2021
Ophthalmic-Biosimilar-Byooviz

FDA Approves Ophthalmic Biosimilar Byooviz

September 21, 2021 – Samsung Bioepis and Biogen's ByoovizTM (ranibizumab-nuna) has received U.S. FDA approval as a biosimilar for Genentech's Lucentis® (ranibizumab)